# BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency

> **NCT01259544** · PHASE2 · COMPLETED · sponsor: **Meridian Bioscience, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Chronic Pancreatitis
- Healthy Volunteers

## Interventions

- **DRUG:** benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
- **DRUG:** benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)

## Key facts

- **NCT ID:** NCT01259544
- **Lead sponsor:** Meridian Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-02
- **Final completion:** 2009-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259544, "BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01259544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*